Anavex Life Sciences Financial results

Anavex Life Sciences Reports Fiscal 2017 Financial Results And Provides Update On Therapeutic Programs

Anavex Life Sciences Reports Fiscal 2017 Financial Results And Provides Update On Therapeutic Programs Conference Call and Webcast Today at 4:30 p.m. ET NEW YORK – December 11, 2017 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases…

Multiple sclerosis

Anavex Life Sciences Announces New Data Related to Multiple Sclerosis Presented at 7th ECTRIMS-ACTRIMS Meeting MSPARIS2017

ANAVEX®2-73 Shown to Protect and Repair Myelin Forming Cells NEW YORK, NY – October 27, 2017 – Anavex Life Sciences Corp. (Anavex or the Company) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types…